510(k) device
LENSAR Laser System - fs 3D (LLS-fs 3D)
Lensar, Inc. · Ophthalmic Femtosecond Laser (OOE, Class II) · First FDA decision May 13, 2010, newest Dec 21, 2018Cataract
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
9
510(k) pathway
Device trials
3
Naming "LENSAR"
MAUDE reports
172
Brand "LENSAR", since 2015
PubMed studies
28
Mentioning "LENSAR"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing LENSAR Laser System - fs 3D (LLS-fs 3D)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 9 decisions filed under this name.
K182795 · Decided Dec 21, 2018 · 81 days after receipt
Device type: Ophthalmic Femtosecond Laser (OOE) · Ophthalmology
5 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "LENSAR", any status and sponsor, newest update first.
LensAR IncorporatedNot on our public-company list
NCT01062412 · 80 participants · Start Dec 2009 · Primary completion Oct 4, 2011
Device: LensAR Laser System · For: Presbyopia; Cataract
Sites: Makati City, Philippines
2 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "LENSAR", and for the whole product code for context.
This brand
172 reports: 8 malfunction, 132 injury, 0 death
Whole product code OOE
4,559 reports: 2,002 malfunction, 2,527 injury, 0 death
Newest reports for this brand
3009026057-2026-00038 · Received Aug 17, 2026 · Event dated Aug 5, 2026
Device type: Ophthalmic Femtosecond Laser (OOE)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Capsular Bag Tear
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "LENSAR"[tiab]. The summary above synthesizes these.
- Femtosecond laser-assisted cataract surgery.
He L, Sheehy K, Culbertson W · Curr Opin Ophthalmol · 2011Review
- [Comparative analysis of the clinical application of two femtosecond laser-assisted cataract operation platforms].
Xu YX, Wang Y, Sun M, et al. · Zhonghua Yan Ke Za Zhi · 2020
- Femtosecond Laser-Assisted Capsulotomy: Histological Comparison of Four Different Laser Platforms.
Hengerer FH, Mittelbronn M, Hansmann ML, et al. · J Refract Surg · 2017Comparative Study
- Changes in endothelial cell density after conventional phacoemulsification and FLACS in eyes with dense cataracts.
Ganesh S, Brar S, Wadhokar S · J Cataract Refract Surg · 2024Randomized Controlled Trial, Comparative Study
- Anterior capsulotomy with an ultrashort-pulse laser.
Tackman RN, Kuri JV, Nichamin LD, et al. · J Cataract Refract Surg · 2011Clinical Trial, Research Support, Non-U.S. Gov't
- Induced inflammation and apoptosis in femtosecond laser-assisted capsulotomies and manual capsulorhexes: an immunohistochemical study.
Toto L, Calienno R, Curcio C, et al. · J Refract Surg · 2015Observational Study
- Cyclorotation during femtosecond laser-assisted cataract surgery measured using iris registration.
Hummel CD, Diakonis VF, Desai NR, et al. · J Cataract Refract Surg · 2017
- Human lens epithelial cell apoptosis and epithelial to mesenchymal transition in femtosecond laser-assisted cataract surgery.
Sun W, Liu J, Li J, et al. · Int J Ophthalmol · 2018
- Sealability of ultrashort-pulse laser and manually generated full-thickness clear corneal incisions.
Teuma EV, Bott S, Edelhauser HF · J Cataract Refract Surg · 2014Research Support, Non-U.S. Gov't
- Efficiency Comparison Between Two Different Lasers and Cataract Surgery Workflows: A Prospective and Retrospective Analysis.
Chapman JM · Clin Ophthalmol · 2025
- Preliminary clinical investigation of cataract surgery with a noncontact femtosecond laser system.
Yu AY, Ni LY, Wang QM, et al. · Lasers Surg Med · 2015Comparative Study, Controlled Clinical Trial
- Femtosecond laser-assisted capsulotomy with capsular marks for toric IOL alignment: Comparison of tensile strength with standard femtosecond laser capsulotomy.
Teuma EV, Gray G, Bedi R, et al. · J Cataract Refract Surg · 2019Comparative Study, Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code OOE.
- VICTUS Femtosecond Laser PlatformTechnolas Perfect Vision GmbH · 510(k) 2020
- LenSx Laser System (8065000944)Alcon Laboratories, Inc. · 510(k) 2025
- Catalys Precision Laser SystemAmo Manufacturing USA, LLC · 510(k) 2023
- Catalys Precision Laser SystemOptimedica Corporation · 510(k) 2016
- TbdLensar, Inc. · 510(k) 2013
- Lensx 550 Laser System. Model 550Lensx Lasers, Inc. · 510(k) 2010
- FEMTO LDV Z8 Femtosecond Surgical LaserSie Ag,Surgical Instrument Engineering · 510(k) 2022
- ELITA Femtosecond Laser System, ELITA Patient InterfaceJohnson & Johnson Surgical Vision, Inc. · 510(k) 2023
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.